- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01013142
Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
A Phase I Randomized, Double-blind, Placebo-controlled Dose Escalation Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously to Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, double-blind, placebo-controlled, multi-center dose escalation study in subjects diagnosed with stable moderate to severe COPD. The study will be conducted in approximately 6 Clinical Research Units (CRUs).
Subjects with a diagnosis of stable moderate to severe COPD will be screened and must demonstrate an improvement in FEV1 after bronchodilator treatment of at least 12% at Screen Visit 1. The subject's degree of dyspnea will be captured on the British Medical Research Council (MRC) questionnaire, and severity will be determined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric criteria. Subjects meeting entry criteria at Screen Visit 1 will be asked to return to the CRU for Screen Visit 2 within 14 days of Visit 1. Subjects confirming entry criteria including degree of COPD severity by spirometry at Screen Visit 2 will be randomized to receive either MN-221 or placebo. Serial spirometry will be performed over the 8 hour treatment period after initiation of study drug administration. Subjects will be discharged from the CRU after completing the Hour 8 study procedures and asked to return approximately 24 hours after initiation of study drug for follow up safety assessments including spirometry. A study diary will be provided to each subject upon discharge from the CRU to complete as instructed and return it to the site at the 24 hour Follow-up Visit.
There will be three dose levels and each will include approximately 16 subjects randomized to receive either MN-221 or placebo in 3:1 ratio (12 subjects receive MN-221:4 subjects receive placebo). A risk/benefit evaluation will be performed by the study's Safety Review Committee at completion of each dose level prior to escalating to the next dose level.
Safety and efficacy will be monitored throughout the treatment period. Blood samples for PK parameters and metabolite identification will be obtained.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85013
- Dedicated Phase I
-
-
California
-
Fullerton, California, United States, 92835
- California Research Medical Group, Inc
-
-
Florida
-
Tamarac, Florida, United States, 33319
- Vita Research Solutions & Medical Center, Inc.
-
Winter Park, Florida, United States, 32789
- Florida Pulmonary Research Institue, LLC
-
-
Kansas
-
Overland Park, Kansas, United States, 66211
- Vince and Associates Clinical Research
-
-
Louisiana
-
Lafayette, Louisiana, United States, 70503
- Gulf Coast Research, LLC
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- SNBL Clinical Pharmacology Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female 40-65 years of age, inclusive;
- History of physician-diagnosed COPD treated for ≥ 3 months ;
- FEV1 ≥ 30% < 80% and FEV1/FVC ratio < 0.7 at screening;
- An increase in FEV1 of at least 12%, over the pre-albuterol FEV1 within 30 minutes after inhalation of albuterol;
- Negative urine pregnancy test for all females unless the subject is post-menopausal (≥ 24 months of spontaneous amenorrhea) or surgically sterile (hysterectomy, bilateral ovariectomy or bilateral tubal ligation);
- Negative urine drug screen for cocaine, PCP, methamphetamine;
- ECG with no evidence of ischemic heart disease or dysrhythmias and otherwise normal or with findings considered not clinically significant at screening;
- QTcB and QTcF < 450 msec;
- No clinical evidence of active ischemic heart disease as determined by the Investigator; and
- Legally effective written informed consent obtained prior to starting any study procedures.
Exclusion Criteria:
- Beta agonist and/or anticholinergic via inhaler or intravenously ≤ 6 hours of screening;
- Sustained release methylxanthine (e.g. Theophylline) or long acting beta agonists ≤ 24 hours prior to screening;
- A diagnosis of clinically significant myocardial or valvular disease; including cardiomyopathy, congestive heart failure, or pulmonary edema;
- Acute exacerbation of COPD requiring emergency treatment ≤ 30 days of screening or hospitalization ≤ 90 days of screening;
- Antibiotic therapy for respiratory infection ≤ 30 days of screening;
- Presence of active respiratory disease such as pneumonia, or acute bronchitis;
- History or presence of tachyarrhythmias, with the exception of sinus tachycardia;
- Hypokalemia defined as a potassium level ≤ 3.0 mmol/L at screening;
- Significant renal, hepatic, endocrine, metabolic, neurologic or other systemic disease;
- Uncontrolled hypertension defined as a blood pressure ≥ 170/100 mm Hg at screening;
- Pregnant or lactating females;
- Participation in another clinical study with an investigational drug within 30 days of screening;
- A known allergy to excipients of the MN-221 drug product;
- A known allergy to other beta agonists;
- Previous exposure to MN-221; or
- Use of beta blockers, MAO inhibitors, or tricyclic antidepressants ≤ 2 weeks prior to screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MN-221
|
i.v.
infusion of MN-221 (300 mcg) or placebo over 1 hour
i.v.
infusion of MN-221 (600 mcg) or placebo over 1 hour
i.v.
infusion of MN-221 (1,200 mcg) or placebo over 1 hour
|
Placebo Comparator: MN-221 Placebo
|
i.v.
infusion of MN-221 (300 mcg) or placebo over 1 hour
i.v.
infusion of MN-221 (600 mcg) or placebo over 1 hour
i.v.
infusion of MN-221 (1,200 mcg) or placebo over 1 hour
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events, cardiac and ECG parameters, vital signs, physical exam and clinical laboratory assessments.
Time Frame: Hour 0 (treatment) through Hour 24 (follow-up)
|
Hour 0 (treatment) through Hour 24 (follow-up)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic parameters of MN-221.
Time Frame: Pre-dose to Hour 24 post-dose
|
Pre-dose to Hour 24 post-dose
|
Forced expiratory volume in one second (FEV1).
Time Frame: Pre-dose to Hour 24 post-dose
|
Pre-dose to Hour 24 post-dose
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Alan W Dunton, MD, MediciNova
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MN-221-CL-010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on MN-221 (Dose Group 1)
-
MediciNovaTerminatedAsthma | Status AsthmaticusUnited States
-
MediciNovaCompleted
-
MediciNovaCompletedChronic Obstructive Pulmonary DiseaseUnited States
-
MediciNovaCompleted
-
Innovent Biologics (Suzhou) Co. Ltd.Completed
-
Stanford UniversityCelgene CorporationRecruitingLeukemia | Leukemia, Myeloid | Monocytic LeukemiaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | HIV SeronegativityBrazil, Peru, Haiti, Trinidad and Tobago
-
University of PennsylvaniaCompleted
-
LTN PHARMACEUTICALS, INC.CompletedProstate CancerUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsUnited States